ConductScience.org, home

Paper39283290

Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).

Troiani A and 5 others. Future Oncol, 2024. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL). Papers, record 39283290. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39283290

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).
PubMed
Journal
Future Oncol
PubMed
Year
2024
PubMed
Publication types
Clinical Trial Protocol, Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.82, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Troiani AAlessandrohttps://orcid.org/0009-0008-8946-9492
2Martinez MMaria
3Ward CCaroline
4Benartzi CWCharlotte Wilhelmhttps://orcid.org/0000-0003-4927-6158
5Pinato DJDavid Jhttps://orcid.org/0000-0002-3529-0103
6Sharma RRohini

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Clinical Trials, Phase I as TopicMajor topic
Janus Kinase 1Major topic
Liver NeoplasmsMajor topic
Protein Kinase InhibitorsMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Piperidines
Pyrimidines
Treatment Outcome
Neoplasm Staging
Acetonitriles
Pyrazoles
Pyrroles

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Imperial College LondonPubMed
IncytePubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04358185Itacitinib in Advanced Hepatocellular CarcinomaBackgroundYes

Source ClinicalTrials.gov

Download CSV of trials

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122300468Management of HCC.J Hepatol2012https://conductscience.org/library/papers/22300468PubMed
216207677The cancer cachexia syndrome: a review of metabolic and clinical manifestations.Nutr Clin Pract2005https://conductscience.org/library/papers/16207677PubMed
334326518The immunological and metabolic landscape in primary and metastatic liver cancer.Nat Rev Cancer2021https://conductscience.org/library/papers/34326518PubMed
434138876Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.PLoS One2021https://conductscience.org/library/papers/34138876PubMed
531449859The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.J Hepatol2020https://conductscience.org/library/papers/31449859PubMed
627932229Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017https://conductscience.org/library/papers/27932229PubMed
727912061Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.Cell2016https://conductscience.org/library/papers/27912061PubMed
837499670Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.Lancet2023https://conductscience.org/library/papers/37499670PubMed
917570226Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology2007https://conductscience.org/library/papers/17570226PubMed
1033479224Hepatocellular carcinoma.Nat Rev Dis Primers2021https://conductscience.org/library/papers/33479224PubMed
1114667750Hepatocellular carcinoma.Lancet2003https://conductscience.org/library/papers/14667750PubMed
1235481940Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.Hepatol Commun2022https://conductscience.org/library/papers/35481940PubMed
1330811474Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.PLoS One2019https://conductscience.org/library/papers/30811474PubMed
1430665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
1526769332A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.J Dermatolog Treat2016https://conductscience.org/library/papers/26769332PubMed
1632782275Targeted therapy for hepatocellular carcinoma.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32782275PubMed
1725858804Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015https://conductscience.org/library/papers/25858804PubMed
1827789678Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.Haematologica2017https://conductscience.org/library/papers/27789678PubMed
1929624699Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018https://conductscience.org/library/papers/29624699PubMed
2033061517Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.Clin Exp Gastroenterol2020https://conductscience.org/library/papers/33061517PubMed

See all 39 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42022176Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies.MedComm (2020)2026https://conductscience.org/library/papers/42022176PubMed
41673081Itacitinib in advanced hepatocellular cancer following first line therapy.NPJ Precis Oncol2026https://conductscience.org/library/papers/41673081PubMed
40620420The Diverse Function of IL-6 in Biological Processes and the Advancement of Cancer.Immune Netw2025https://conductscience.org/library/papers/40620420PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39283290

GET https://conductscience.org/api/papers/v1/39283290/references?page=2